Asset profile

Empagliflozin · Jardiance

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Chronic Kidney Disease, Type 2 Diabetes, Heart Failure

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

Also in development:Atherosclerotic Cardiovascular Disease · Phase 2

How the evidence outlook works ↗

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (8)
August 2026 (1)
Phase 2Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-08-20 · NCT06926660 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)
Phase 3Heart FailureActive not recruiting
Est. primary completion 2026-09-30 · NCT05182658 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)
Phase 2/3Empagliflozin in Cardiorenal Syndrome Type 1Recruiting
Est. primary completion 2026-11-30 · NCT06030843 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (5)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07093476 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Heart FailureRecruiting
Est. primary completion 2026-12-01 · NCT07692256 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-12-30 · NCT05786443 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)Recruiting
Est. primary completion 2026-12-30 · NCT07336797 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT05392764 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (9)
February 2027 (1)
Phase 2Heart FailureRecruiting
Est. primary completion 2027-02-01 · NCT07372040 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 3Cardiogenic ShockRecruiting
Est. primary completion 2027-03-16 · NCT05879276 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (2)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Heart FailureRecruiting
Est. primary completion 2027-04-30 · NCT07038356 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-05-01 · NCT05715814 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Heart FailureRecruiting
Est. primary completion 2027-05-31 · NCT05138575 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-09-30 · NCT07749014 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2027-11 · NCT06024746 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 3Congenital Heart DiseaseNot yet recruiting
Est. primary completion 2027-12 · NCT06955260 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (6)
January 2028 (2)
Phase 2Non-Alcoholic Fatty Liver DiseaseRecruiting
Est. primary completion 2028-01-01 · NCT06355310 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLDNot yet recruiting
Est. primary completion 2028-01-01 · NCT03867487 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (1)
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-02 · NCT07304817 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2028-04 · NCT07756294 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2028-05-22 · NCT06424288 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-08-30 · NCT06531824 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (3)
February 2029 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2029-02-04 · NCT06935370 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2029 (1)
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07060417 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2029-12-14 · NCT07064473 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
July 2030 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2030-07 · NCT06992440 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.